UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort

Seminars in arthritis and rheumatism, 2015-08, Vol.45 (1), p.28-34

2015

Volltextzugriff (PDF)

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Journal of rheumatology, 2003-12, Vol.30 (12), p.2563

2003

Volltextzugriff (PDF)

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

Annals of the rheumatic diseases, 2014-08, Vol.73 (8), p.1549-1551

2014

Volltextzugriff (PDF)

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience

Journal of rheumatology, 2006-05, Vol.33 (5), p.854

2006

Volltextzugriff (PDF)

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

Rheumatology international, 2017-02, Vol.37 (2), p.213-218

2017

Volltextzugriff (PDF)

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

Journal of rheumatology, 2004-06, Vol.31 (6), p.1098

2004

Volltextzugriff (PDF)

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Annals of the rheumatic diseases, 2014-12, Vol.73 (12), p.2174-2177

2014

Volltextzugriff (PDF)

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Annals of the rheumatic diseases, 2018-05, Vol.77 (5), p.658-666

2018

Volltextzugriff (PDF)

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability

Journal of rheumatology, 2004-08, Vol.31 (8), p.1532

2004

Volltextzugriff (PDF)

Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers

The American journal of gastroenterology, 2012-03, Vol.107 (3), p.379-386

2012

Volltextzugriff (PDF)

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study

Journal of rheumatology, 2006-04, Vol.33 (4), p.659

2006

Volltextzugriff (PDF)

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry

Journal of rheumatology, 2011-07, Vol.38 (7), p.1273-1281

2011

Volltextzugriff (PDF)

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results

Journal of rheumatology, 2003-04, Vol.30 (4), p.691

2003

Volltextzugriff (PDF)

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

The New England journal of medicine, 2000-11, Vol.343 (22), p.1586-1593

2000

Volltextzugriff (PDF)

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

Arthritis care & research (2010), 2011-03, Vol.63 (3), p.373-382

2011

Volltextzugriff (PDF)

Response to: ‘Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?’ by Fleishman and Yazici

Annals of the rheumatic diseases, 2014-09, Vol.73 (9), p.e55-e55

2014

Volltextzugriff (PDF)

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial

Journal of rheumatology, 2012-07, Vol.39 (7), p.1326-1333

2012

Volltextzugriff (PDF)

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

The New England journal of medicine, 1997-07, Vol.337 (3), p.141-147

1997

Volltextzugriff (PDF)

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial

Journal of rheumatology, 2011-06, Vol.38 (6), p.990-996

2011

Volltextzugriff (PDF)

Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries

Journal of rheumatology, 2011-01, Vol.38 (1), p.21-28

2011

Volltextzugriff (PDF)

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

Current medical research and opinion, 2006-01, Vol.22 (1), p.185-198

2006

Volltextzugriff (PDF)

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

Current medical research and opinion, 2006-01, Vol.22 (1), p.169-183

2006

Volltextzugriff (PDF)

Durability and rapidity of response to anakinra in patients with rheumatoid arthritis

Drugs (New York, N.Y.), 2004-01, Vol.64 (22), p.2493-2501

SCHIFF, Michael H

2004

Volltextzugriff (PDF)

A retrospective analysis of low-field strength magnetic resonance imaging and the management of patients with rheumatoid arthritis

Current medical research and opinion, 2007-05, Vol.23 (5), p.961-968

2007

Volltextzugriff (PDF)

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Arthritis and rheumatism, 2006-07, Vol.54 (7), p.2136-2146

2006

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(78)

Sprache

Englisch
(78)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(78)
Science & Technology
(74)
Female
(73)
Life Sciences & Biomedicine
(73)
Middle Aged
(66)
Adult
(52)
Aged
(49)
Treatment Outcome
(43)
Biological And Medical Sciences
(40)
Medical Sciences
(40)
Arthritis, Rheumatoid - Drug Therapy
(30)
Rheumatology
(27)
Double-Blind Method
(22)
Pharmacology. Drug Treatments
(22)
Antirheumatic Agents - Therapeutic Use
(19)
Rheumatoid Arthritis
(19)
Diseases Of The Osteoarticular System
(18)
Inflammatory Joint Diseases
(18)
Drug Therapy, Combination
(16)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability

Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers

Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry

Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis

Response to: ‘Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability?’ by Fleishman and Yazici

Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial

Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registries

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

Durability and rapidity of response to anakinra in patients with rheumatoid arthritis

A retrospective analysis of low-field strength magnetic resonance imaging and the management of patients with rheumatoid arthritis

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Aktive Filter

Suchergebnisse filtern